We are proud to announce the Winners for the 2018 Edison Awards™. These Gold, Silver and Bronze Winners were chosen as the "best of the best" by the world's top senior business executives, academics, and innovation professionals.
I am pleased to announce that two of Natera’s flagship products, Panorama® and Signatera™ have been recognized for technological innovation in the areas of reproductive health and personalized cancer care by the prestigious Edison Awards committee.
Natera was the only company in healthcare to receive more than one Edison award, and the only company among our competitors to receive this award in 2018. This achievement is a direct reflection of our commitment to innovations that address critical unmet medical needs and better serve patients.
- Our Panorama® non-invasive prenatal test (NIPT) for twins won the bronze award for innovation based on our enhanced screening capability for twin pregnancies. We offer the first and only NIPT that reports early, accurate zygosity and individual fetal sex for twin pregnancies. Our test analyzes each
twin’s DNA to help clinicians identify pregnancies at high risk for serious complications that require specialized care. In 2017, Panorama received a silver award in 2017 for being the only NIPT that differentiates between maternal and fetal DNA and detecting high-risk conditions that other tests cannot, including triploidy, vanishing twins, and molar pregnancies, and effectively yielding the highest sensitivity and specificity in the industry.
- Our Signatera™ research-use only circulating tumor DNA (ctDNA) assay won the committee’s highest honor - the gold award for its ability to provide a unique, customized blood test tailored to match the mutations found in an individual’s tumor tissue, which maximizes sensitivity and specificity in detecting minimal residual disease, disease recurrence and treatment response. Signatera differs from currently available liquid biopsy assays, which test for a generic panel of genes independent of an individual’s tumor. Signatera’s innovative approach was published last year in Nature and showed an ability to discriminate responders from non-responders, detect residual disease and predict recurrence up to 11 months prior to radiographic confirmation with 93% sensitivity and zero false positives. This is an exciting time for us in oncology. We recently shared research data for bladder and colon cancer at the annual American Association of Cancer Research. The findings were consistent with the results we published in Nature a year ago, and demonstrated the pan-cancer capability of Signatera.
The Edison Awards symbolize the persistence and excellence personified by Thomas Edison, which is consistent which our mission to serve patients through cutting edge bioinformatics. The winners of this year you may